Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Ascendis Pharma A-S
CEO
Mr. Jan Moller Mikkelsen
Employees
879
Industry
Biotechnology
Sector
Healthcare
Market cap
$8B
Company details
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$327.43M
Cost of goods (CoG)
-$49.69M
Gross profit (GP)
$277.74M
Operating expense (OE)
-$517.48M
Research and development (R&D)
-$318.59M
General and administrative (G&A)
-$198.89M
Operating income (OI)
-$315.76M
Other income expense (OIE)
-$8.59M
Pretax income (PI)
-$416.94M
Tax (TAX)
-$9.55M
Net income (NI)
-$426.49M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$9.49
Margin profit
-154.12%
52 week low
$112.93
52 week high
$159.470001
50-day simple moving average
$130.81
200-day simple moving average
$132.28
Percent held by insiders
0.73%
Percent held by institutions
107.12%
Dividend yield
0.00%
